| Bioactivity | Docetaxel-d9 is the deuterium labeled Docetaxel. Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC50 of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity[1][3]. | ||||||||||||
| Invitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. | ||||||||||||
| Name | Docetaxel-d9 | ||||||||||||
| CAS | 940867-25-4 | ||||||||||||
| Formula | C43H44D9NO14 | ||||||||||||
| Molar Mass | 816.93 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Docetaxel-d9
CAS: 940867-25-4 F: C43H44D9NO14 W: 816.93
Docetaxel-d9 is the deuterium labeled Docetaxel. Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.